Patent Grant
7037943
The invention relates to methods for providing a device or composition to a retina.
The retina is the innermost layer of the wall of the eyeball located in the posterior segment of the eye. Developed as an outgrowth from the brain, the retina contains nervous tissue, specifically, light-sensitive cells (photoreceptors) and complex neural networks. These networks provide visual information and send impulses through the optic nerve to the brain.
Degenerative diseases of the retina, such as retinitis pigmentosa, age-related macular degeneration, and hereditary retinal degenerations cause degeneration and death of the photoreceptor cells, resulting in decreased visual function. Fortunately, even in end-stage disease, numerous neuronal cells in the inner retina survive. However, because of loss of the photoreceptors, light stimulation does not occur and the neuronal cells must be artificially stimulated to restore some degree of visual function.
The neuronal cells may be stimulated, either from the outer surface of the retina or from the so-called subretinal space. One technique for subretinal stimulation uses semiconductor microphotodiode arrays (SMA) as described in Peyman et al., Ophthalmic Surgery and Lasers, 1998, vol. 29, p. 234, which is expressly incorporated by reference herein in its entirety. These arrays are fabricated by standard photomask and etch techniques, and can be produced with thicknesses ranging from about 10-200 μm and sizes varying from about 0.5-5 mm in diameter. The arrays are separated into subunits, which create a pixel density of over 1000 subunits/mm2. The subunits have no electrical connection; they are powered by incident light having a wavelength between 500-1100 mm. Another technique for retinal stimulation uses an electrode array to electrically stimulate the neurofiber layer of the retina. The array has 25 platinum disks arranged in a 5×5 square, as reported by Majji et al., Investigative Ophthalmology and Visual Science, 1999, vol. 40, p. 2073. The improved surface of the platinum disk forms a planar array of stimulating electrodes in a silicon matrix that is less than 1 mm thick. Twenty-five wires originating from the disk form a cable which extends from the array and is at least 10 cm long and 600 mm thick. To implant the array into the eye, the surface of the implant (3×5 mm) is placed over and is fixed to the retina either by mechanical fasteners such as pins or tacks, or by bioadhesives.
There are, however, several disadvantages of implanting the aforementioned types of arrays into the subretinal space. One disadvantage is that the implant may interfere with nutrition of the retina, since nutrients come partially from the choroid (the back of the retina). Fenestrations, or small openings in the array, can help to maintain nutrient accessibility to the retina. Implanting the electrode type of array over the surface of the retina has additional drawbacks. One drawback is that fixing the array over the retina is very difficult. If pins or other mechanical fasteners are used, they should penetrate the entire retina and reach the scleral wall in order to secure the array, but this increases the risk of hemorrhage from the retinal and choroidal circulation. The increased fibrous proliferation around both the fasteners and the array also causes localized scarring and traction on the retina. Another disadvantage is that electrical stimulation in the subretinal space may not adequately excite the ganglion cells and the neurofiber layer, which are located in the outer portion of the retina.
Drugs such as gancyclovir or various steroids can also be administered to the patient to attempt to prevent, halt, or alleviate the pathological process. Ocular drugs may be administered systemically, parenterally, or topically. Alternatively or additionally, the drugs may be administered in a slow release formulation.
While current methods exist for treating patients experiencing a loss in visual function due to retinal pathology, several problems still remain. Thus, additional methods to improve visual function, while decreasing or eliminating these problems, are desirable.
The invention relates to a method to provide an interventional or therapeutic substance to patients who have experienced decreased visual function due to retinal pathology or injury. The invention is also directed to a method for treating or preventing retinal pathology or injury in a mammal by surgically affixing a therapeutic or preventive substance under an internal limiting membrane in the eye to contact and stimulate the retina.
The inventive method provides the retinal stimulator substance to a mammalian eye by visualizing the internal limiting membrane of the eye, locating the retinal stimulator between the internal limiting membrane and the retina, and securing the substance under the internal limiting membrane. The method thus locates, contains, and secures a retinal stimulator substance in proximity to the retina, all by using a space provided by the internal limiting membrane in the eye.
In one embodiment, the substance is an array that is photostimulated to excite the retina. In another embodiment, the substance is an array that is electrically stimulated to excite the retina. In yet another embodiment, the substance is a drug that directly or indirectly stimulates the retina, for example, a drug that is formulated in a vehicle for slow-release delivery.
The inventive method takes advantage of the physiological placement of the internal limiting membrane in the eye. Previous surgical implant methods had removed the internal limiting membrane. However, the inventive method not only retains the internal limiting membrane, but also takes advantage of the space between it and the adjacent retinal layers to implant a therapeutic or preventative substance. In this way, non-physiological mechanical or chemical fasteners are not needed to locate and secure the implanted substance in place. Thus, there are no devices or compositions which may cause bleeding from the choroid or which may promote retinal traction originating from the cells migrating from the choroid through the mechanical pins, both of which are problems in current methods.
Another improvement using the inventive method is that the substance implanted is in direct contact with the neurofiber layer and ganglion cells of the retina. This advantageously enhances their stimulation, since the distance between the substance and its target is decreased. For example, when electrical arrays are implanted, there is enhanced qualitative and quantitative cell stimulation because the stimulus is close enough to reach ganglion cells and the neurofiber layer that is located a distance of about 10-50 μm away.
Still anther improvement is that the inventive method eliminates the need for external stimulation, as is used with currently available diode arrays.
These and other advantages will be apparent from the following figures and detailed description.
With reference to
The most sensitive portion of the retina 20 is the macula lutea 17, which is located in the center of the posterior part of the retina 20. The inner surface of the retina 20, near the border of the optic nerve 15, has a shallow round depression, the fovea 41. The fovea 41 is surrounded by the central area, distinguished by the great number of ganglion cells and by the general refinement and even distribution of the structural elements, especially the rod cells and the cone cells. About one-tenth inch inside the fovea 41 is the point of entrance of the optic nerve 15 and its central artery. At this point, the retina 20 is incomplete and forms the blind spot.
With reference to
The inventive method takes advantage of the adjacent positions of the neurofiber layer 109 and ganglion cells 108 with the inner limiting membrane 110 to provide a space 120 into which a substance 130 for treating the retina 20, such as an array for electrostimulation of the retina, can be implanted and secured. The potential for and use of this space 120 in implanting an array or any other material has heretofore been unrecognized and unappreciated.
In the method, the patient is prepared for surgery, typically by providing a topical anesthesia to the eye and dilating the pupil. The eyeball is exposed and the vitreous is removed from the vitreous cavity 8 by standard techniques known to one skilled in this art. The internal limiting membrane 110 is then rendered visible to the surgeon, typically by staining. Any water soluble stain which stains the basement membrane of the internal limiting membrane 110 can be used, for example, indocyanine green, trypan blue, methylene blue, etc. The stain, for example one or two drops, is placed into the eye to allow visualization of the internal limiting membrane 110. A small incision, typically less than about 0.5 mm in diameter, is made into the internal limiting membrane 110 in the area of the macula lutea 17.
In current methods for treating a macular hole, the internal limiting membrane 110 is separated and removed using forceps.
To create a space where an array can be placed under the internal limiting membrane 110, the internal limiting membrane 110 can be separated from the retina 20 by a blunt-tipped spatula or a cannula for injection of a liquid.
In the inventive method, however, instead of cutting and removing the internal limiting membrane 110 as is routinely done, the internal limiting membrane 110 is left in place and is, in fact, used to locate the implanted substance 130. A small incision 132 is made in the internal limiting membrane 110, and the membrane 110 is then separated from the adjacent neurofiber layer 109. The substance 130 is implanted, and because the incision used for separation of the internal limiting membrane is small, the substance 130 is inserted in a secure fit. The internal limiting membrane is then repositioned over the substance 130. Furthermore, the repositioned internal limiting membrane 110 also secures the implanted substance 130 to the neurofiber layer 109 and ganglion cells 108. After the substance 130 is located and secured under the internal limiting membrane 110, the vitreous cavity 8 can be re-filled with fluid, for example, air. This fluid is subsequently absorbed and is replaced by body fluids.
In the inventive method, positioning and replacement of the internal limiting membrane 110 over the implanted substance 130 either eliminates the need for an adhesive, or allows a smaller quantity of adhesive to be used than if the internal limiting membrane was removed. If desired, however, an adhesive can also be applied to close the incision, but is not placed between the substance 130 and the retina 20. The adhesive can be, for example, a commercial fibrin sealant, autologous fibrin, Cell-Tak, photocurable glues, polyethylene glycol hydrogels, as described in Margalit et al., Retina, 2000, vol. 20, p. 469, which is expressly incorporated by reference herein in its entirety.
If the substance 130 implanted is an array, it may be with or without external connections. For example, an array with electrode connectors having a length of about 50 μm to about 100 μm may be implanted. An array can be of any type as is know to one of skill in this art, such as the semiconductor microphotodiode array that is described by Peyman et al., Ophthalmic Surgery and Lasers, 1998, vol. 29, p. 234, which is expressly incorporated by reference herein in its entirety. An array as small as 10 μm can be implanted. Alternatively, multiple small arrays, with a total size of up to about 8 mm, may be implanted. Their position can subsequently be organized and oriented magnetically. The array can be fabricated to be fenestrated, or it can be without fenestrations. The individual array can be positive-intrinsic layer-negative (PiN), mixed, negative-intrinsic layer-positive (NiP), or uniform. In the array, light absorption occurs in the front and the electricity runs to the side or the back. If electrode arrays are used, the technology described by Majii et al. is utilized, with connectors to penetrate the neurofiber layer 109 of the retina 20.
The retinal stimulator substance 130 may also be a drug. As one example, the drug may be an α-adrenergic agonist or a β-adrenergic agonist, as disclosed in U.S. Pat. No. 6,066,675 which is expressly incorporated by reference herein in its entirety. As other examples, the drug may be one or more antiinflammatory agents and/or antiproliferative agents, as is known to one skilled in the art. The drug may be implanted either alone or may be incorporated into a drug delivery system, such as a slow-release system or formulation. Examples of such systems are known to one of skill in this art and include, but are not limited to, a capsule, a bead, a liposome, a sphere, and/or a dissolvable biocompatible polymer sheet.
The inventive method provides several advantages. It eliminates the need for surgical removal of the internal limiting membrane 110. Furthermore, the inventive method takes advantage of the presence of the internal limiting membrane 110 to provide a “pocket” or space 120 for implanting the substance 130. If the substance 130 is an array, the approximation of the array to the ganglion cells 108 and the neurofiber layer 109 can better amplify the stimulation of these structures. The array thus placed requires less electrical power than is required with arrays implanted by previously known methods such as using adhesives. The signal generated, being located directly adjacent its retinal target site, is less likely to be attenuated and hence will be more efficacious. The array 130 is also securely maintained in the space 120 without the need for either mechanical fixatives, such as retinal tacks, or chemical fixatives, such as adhesives. This eliminates the problems of bleeding and/or tearing that are known to occur when mechanical fasteners such as tacks or pins are used. The inventive method also eliminates the problems associated with the use of adhesives, namely, that adhesives come off and the substance becomes dislodged from its original site of implantation, and that adhesives serve as insulators and hence interfere with transmission of an electrical signal from an array to the retina 20.
It should be understood that the embodiments of the present invention shown and described in the specification are only preferred embodiments of the inventor who is skilled in the art and are not limiting in any way. Therefore, various changes, modifications or alterations to these embodiments may be made or resorted to without departing from the spirit of the invention and the scope of the following claims.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1325669 | Green | Dec 1919 | A |
| 2760483 | Tassicker | Aug 1956 | A |
| 3594823 | Collins | Jul 1971 | A |
| 3628193 | Collins | Dec 1971 | A |
| 3766311 | Boll | Oct 1973 | A |
| 3848608 | Leonard | Nov 1974 | A |
| 3914800 | Collins | Oct 1975 | A |
| 4001867 | Kravitz et al. | Jan 1977 | A |
| 4211474 | Le Goff | Jul 1980 | A |
| 4251887 | Anis | Feb 1981 | A |
| 4272910 | Danz | Jun 1981 | A |
| 4551149 | Sciarra | Nov 1985 | A |
| 4600004 | Lopez et al. | Jul 1986 | A |
| 4601545 | Kern | Jul 1986 | A |
| 4628933 | Michelson | Dec 1986 | A |
| 4679572 | Baker, Jr. | Jul 1987 | A |
| 4681102 | Bartell | Jul 1987 | A |
| 4750498 | Graham | Jun 1988 | A |
| 4810050 | Hooper | Mar 1989 | A |
| 4832202 | Newman et al. | May 1989 | A |
| 4836202 | Krasner | Jun 1989 | A |
| 4873448 | Shirai | Oct 1989 | A |
| 4936827 | Grimm et al. | Jun 1990 | A |
| 4978842 | Hinton et al. | Dec 1990 | A |
| 5016633 | Chow | May 1991 | A |
| 5024223 | Chow | Jun 1991 | A |
| 5109844 | de Juan, Jr. et al. | May 1992 | A |
| 5130528 | Phillips, Jr. | Jul 1992 | A |
| 5130776 | Popovic et al. | Jul 1992 | A |
| 5159927 | Schmid | Nov 1992 | A |
| 5223728 | Gempe | Jun 1993 | A |
| 5256882 | Miyasaka | Oct 1993 | A |
| 5273530 | Del Cerro et al. | Dec 1993 | A |
| 5288291 | Teoh | Feb 1994 | A |
| 5338991 | Lu | Aug 1994 | A |
| 5351309 | Lee et al. | Sep 1994 | A |
| 5397350 | Chow et al. | Mar 1995 | A |
| 5411540 | Edell et al. | May 1995 | A |
| 5476494 | Edell et al. | Dec 1995 | A |
| 5484403 | Yoakum et al. | Jan 1996 | A |
| 5491349 | Komoto et al. | Feb 1996 | A |
| 5556423 | Chow et al. | Sep 1996 | A |
| 5648655 | Rostoker | Jul 1997 | A |
| 5676679 | Simon et al. | Oct 1997 | A |
| 5717201 | Lin et al. | Feb 1998 | A |
| 5814017 | Kashmer | Sep 1998 | A |
| 5817075 | Giungo | Oct 1998 | A |
| 5837995 | Chow et al. | Nov 1998 | A |
| 5865839 | Doorish | Feb 1999 | A |
| 5895414 | Sanchez-Zambrano | Apr 1999 | A |
| 5895415 | Chow et al. | Apr 1999 | A |
| 5930937 | Bowersock | Aug 1999 | A |
| 5935155 | Humayun et al. | Aug 1999 | A |
| 5941250 | Aramant et al. | Aug 1999 | A |
| 5944747 | Greenberg et al. | Aug 1999 | A |
| 5962027 | Hughes | Oct 1999 | A |
| 6032062 | Nisch | Feb 2000 | A |
| 6066675 | Wen et al. | May 2000 | A |
| 6159218 | Aramant et al. | Dec 2000 | A |
| 6035236 | Jarding et al. | May 2001 | A1 |
| 6230057 | Chow et al. | May 2001 | B1 |
| 6280449 | Blake | Aug 2001 | B1 |
| 6298270 | Nisch et al. | Oct 2001 | B1 |
| 6347250 | Nisch et al. | Feb 2002 | B1 |
| 6387101 | Butts et al. | May 2002 | B1 |
| 6389317 | Chow et al. | May 2002 | B1 |
| 6393327 | Scribner | May 2002 | B1 |
| 6427087 | Chow et al. | Jul 2002 | B1 |
| 20020055724 | Hughes | May 2002 | A1 |
| 20020147464 | Peyman | Oct 2002 | A1 |
| Number | Date | Country |
|---|---|---|
| 195 29 371 | Feb 1997 | DE |
| 0 084 621 | Nov 1982 | EP |
| 0 233 789 | Aug 1987 | EP |
| 0 501 904 | Sep 1992 | EP |
| 2 229 543 | Sep 1990 | GB |
| WO 9915119 | Apr 1999 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20020147464 A1 | Oct 2002 | US |
